200 / 266
169
16
Room 513: Monday, February 29
10:30 am–12:00 pm
Wyatt Technology Corporation
Get it Right the First Time - Enhancing Protein Binding and
Structural Studies with the Light-Scattering Toolkit
Biophysical binding studies utilizing surface plasmon resonance (SPR), bio-
layer interferometry (BLI), isothermal titration calorimetry (ITC), and relat-
ed techniques are central to the study of protein-protein, protein-DNA
and similar biomolecular interactions. Though these are well-established
techniques, in a variety of circumstances, binding measurements may be
ambiguous or even fail to provide useful data. Wasted measurements can
end up being costly in terms of consumables and time.
Small-angle X-ray scattering (SAXS) and small-angle neutron scattering
(SANS) are powerful techniques for studying biomolecular structure. SAXS
and SANS usually require precious beam time at large facilities, leaving
little room for error where the sample preparation is concerned. Poor
samples provide poor SAXS/SANS data, but the opportunity to utilize the
X-ray or neutron beam may never be recovered.
One thing that SAXS and SANS have in common with SPR, BLI and ITC, is
the urgent need to verify sample quality and aggregation state in solu-
tion prior to carrying out structural or binding measurements. This semi-
nar discusses a suite of complementary techniques, all based on light
scattering, that are useful in assessing and troubleshooting many of the
underlying characterization issues. Multi-angle light scattering (MALS)
and dynamic light scattering (DLS) can help researchers assess solu-
tion quality prior to running binding or structural experiments, qualify
aggregation behavior of analytes, and characterize complex interactions
that may not be amenable to standard characterization methodology.
Judicious use of the biophysical light-scattering toolkit is essential for
robust and reliable interaction and structure studies.
Speaker
Sophia Kenrick, Application Specialist, Wyatt Technology Corporation
12:30 pm–2:00 pm
Nanion Technologies GmbH
Ion Channel Drug Discovery - Beyond the Bottlenecks and
Ready for CiPA
Nanion Technologies is one of the leading providers of automated
patch clamp systems, offering a diverse product portfolio ranging from
single channel recordings to HTS-compatible ion channel drug discov-
ery. During this workshop, we will show how to push the boundaries of
patch clamp-based ion channel high throughput screening projects of
various voltage- and ligand gated targets, and how to get ready for CiPA-
compliant safety screening going well beyond hERG.
Cardiac arrhythmic risk assessment is a hot topic these days calling for
new screening strategies. With the CiPA-initiative, the panel of cardiac
ion channels to consider have drastically expanded, consequently requir-
ing increased data throughput for early compound safety prediction.
The
SyncroPatch 384/768PE
, an automated patch clamp platform
recording from up to 768 cells simultaneously, allows the highest data
throughput on the market supporting HTS of ion channel active com-
pounds and early safety assessment on cardiac channels. Examples will
be shown, where six different cardiac channels were recorded using one
single plate, in one single run.
Patchliner
, a medium-throughput APC platform, supports automated
current clamp recordings, experiments at physiological temperatures,
and a minimal cell usage, making it the ideal partner for safety testing
on stem cell derived cardiomyocytes. Additionally, the CardioExcyte 96,
a hybrid system combining impedance-based and EFP recordings from
beating cardiomyocyte networks from 96 recording wells in parallel, has
proven a versatile tool for safety and toxicity screening applications serv-
ing as a powerful tool complementing APC.
The
SURFE2R
technology allows direct and functional measurements
electrogenic transporter. Hands-on experiments on the SURFE2R will be
shown. Also membrane fragments from Chantest, a Charles River com-
pany, will be used.
Join our workshop to learn more about new safety screening strategies
and how to keep up with the increasing demands on cardiac safety and
toxicity screening.
Speakers
Maria Barthmes, Nanion Technologies GmbH
Andrea Brüggemann, Nanion Technologies GmbH
Niels Fertig, Nanion Technologies GmbH
Markus Rapedius, Nanion Technologies GmbH